Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer

Table 4 Comparison of tumor markers before and after treatment in two groups

Index	Observation group (n = 40)	Control group (n = 40)	t value	P value
CA199 (mg/L)
Before treatment	110.43 ± 21.32	108.28 ± 19.82	0.467	0.642
1 wk after treatment	71.22 ± 17.28a	88.01 ± 13.34a	-4.864	0.000
1 mo after treatment	44.49 ± 15.52a,d	69.32 ± 12.10a,d	-7.980	0.000
CEA (ng/L)
Before treatment	46.69 ± 7.80	47.05 ± 8.00	-0.204	0.839
1 wk after treatment	32.21 ± 6.65a	40.40 ± 7.71a	-5.087	0.000
1 mo after treatment	11.38 ± 3.03a,d	28.83 ± 6.62a,d	-15.159	0.000
NSE (mg/L)
Before treatment	22.23 ± 3.54	22.40 ± 3.70	-0.210	0.834
1 wk after treatment	17.39 ± 3.11a	19.40 ± 2.83a	-3.023	0.003
1 mo after treatment	12.23 ± 2.29a,d	17.73 ± 2.69a,d	-9.847	0.000
EGFR (mg/L)
Before treatment	22.43 ± 5.54	22.15 ± 4.48	0.249	0.804
1 wk after treatment	16.67 ± 2.11a	19.22 ± 2.17a	-5.328	0.000
1 mo after treatment	6.60 ± 1.92a,d	11.11 ± 2.01a,d	-10.262	0.000

^aP < 0.05 vs before treatment.

^dP < 0.05 vs 1 wk after treatment.

CA199: Carbohydrate antigen 199; CEA: Carcinoembryonic antigen; NSE: Neuron-specific enolase; EGFR: Epidermal growth factor receptor.